title: Immunosuppressive and autoimmune effects of thimerosal in mice.
abstract: The possible health effects of the organic mercury compound thimerosal (ethylmercurithiosalicylate), which is rapidly metabolized to ethylmercury (EtHg), have recently been much debated and the effect of this compound on the immune system is largely unknown. We therefore studied the effect of thimerosal by treating A.SW (H-2s) mice, susceptible to induction of autoimmunity by heavy metals, with 10 mg thimerosal/L drinking water (internal dose ca 590 microg Hg/kg body weight/day) for up to 30 days. The lymph node expression of IL-2 and IL-15 mRNA was increased after 2 days, and of IL-4 and IFN-gamma mRNA after 6 and 14 days. During the first 14 days treatment, the number of splenocytes, including T and B cells as well as Ig-secreting cells decreased. A strong immunostimulation superseded after 30 days treatment with increase in splenic weight, number of splenocytes including T and B cells and Ig-secreting cells, and Th2- as well as Th-1-dependent serum immunoglobulins. Antinucleolar antibodies (ANoA) targeting the 34-kDa nucleolar protein fibrillarin, and systemic immune-complex deposits developed. The H-2s strains SJL and B10.S also responded to thimerosal treatment with ANoA. The A.TL and B10.TL strain, sharing background genes with the A.SW and B10.S strain, respectively, but with a different H-2 haplotype (t1), did not develop ANoA, linking the susceptibility to H-2. Thimerosal-treated H-2s mice homozygous for the nu mutation (SJL-nu/nu), or lacking the T-cell co-stimulatory molecule CD28 (B10.S-CD28-/-), did not develop ANoA, which showed that the autoimmune response is T-cell dependent. Using H-2s strains with targeted mutations, we found that IFN-gamma and IL-6, but not IL-4, is important for induction of ANoA by thimerosal. The maximum added renal concentration of thimerosal (EtHg) and inorganic mercury occurred after 14 days treatment and was 81 microg Hg/g. EtHg made up 59% and inorganic mercury 41% of the renal mercury. In conclusion, the organic mercury compound thimerosal (EtHg) has initial immunosuppressive effects similar to those of MeHg. However, in contrast to MeHg, thimerosal treatment leads in genetically susceptible mice to a second phase with strong immunostimulation and autoimmunity, which is T-cell dependent, H-2 linked and may at least partly be due to the inorganic mercury derived from the metabolism of ethyl mercury.
authors.affiliation: Department of Molecular and Clinical Medicine, Molecular and Immunological Pathology (AIR), Linköping University, SE-581 85 Linköping, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Havarinasab
authors.forename: B
authors.initials: B
authors.lastname: Häggqvist
authors.forename: E
authors.initials: E
authors.lastname: Björn
authors.forename: K M
authors.initials: KM
authors.lastname: Pollard
authors.forename: P
authors.initials: P
authors.lastname: Hultman
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood / Q000187:drug effects / Q000276:immunology; D015551:Autoimmunity; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D018122:B7-1 Antigen / Q000378:metabolism; D001808:Blood Vessels / Q000737:chemistry / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002450:Cell Communication / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D007074:Immunoglobulin G / Q000737:chemistry / Q000187:drug effects; D007147:Immunoglobulin Light Chains / Q000097:blood / Q000187:drug effects / Q000276:immunology; D007166:Immunosuppressive Agents / Q000276:immunology* / Q000494:pharmacology; D007371:Interferon-gamma / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D007668:Kidney / Q000098:blood supply / Q000737:chemistry / Q000187:drug effects; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008198:Lymph Nodes / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008643:Mesentery / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D016297:Mutagenesis, Site-Directed / Q000235:genetics / Q000276:immunology; D009154:Mutation / Q000187:drug effects; D009929:Organ Size / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D018121:Receptors, Cytokine / Q000235:genetics / Q000276:immunology; D013154:Spleen / Q000098:blood supply / Q000166:cytology / Q000187:drug effects; D013849:Thimerosal / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology*
chemical_list: D000974:Antibodies, Antinuclear; D018122:B7-1 Antigen; D007074:Immunoglobulin G; D007147:Immunoglobulin Light Chains; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D018121:Receptors, Cytokine; D015847:Interleukin-4; D013849:Thimerosal; D007371:Interferon-gamma